acut
hepat
injuri
diagnos
alt
time
upper
refer
limit
alp
time
appropri
upper
refer
limit
iib
total
bilirubin
mgdl
pt
upper
refer
limit
individu
viral
hepat
absenc
factor
affect
result
indic
sever
liver
injuri
iib
direct
bilirubin
need
rule
caus
increas
total
bilirubin
hemolysi
differenti
hepat
injuri
obstruct
jaundic
iib
acetaminophen
toxic
persist
increas
increas
pt
day
ingest
indic
sever
liver
injuri
iib
initi
evalu
acut
hepat
injuri
includ
detail
drug
histori
viral
marker
igm
antihav
igm
antihbc
hbsag
antihcv
iib
need
postexposur
prophylaxi
turnaround
time
igm
antihav
h
iiic
iiie
costeffect
base
preval
laboratori
may
use
total
antibodi
hav
antihbc
initi
perform
igm
antibodi
one
posit
turnaround
time
need
met
iiie
diagnosi
acut
hcv
infect
patient
clinic
pictur
acut
hepat
injuri
presumpt
made
neg
hav
hbv
marker
recent
exposur
either
neg
antihcv
posit
hcv
rna
neg
antihcv
initi
present
develop
posit
antihcv
within
month
iiib
test
hdv
limit
patient
posit
hbsag
atyp
clinic
cours
high
risk
hdv
infect
iib
iie
ast
alt
valu
higher
normal
rare
viral
hepat
common
toxin
ingest
especi
acetaminophen
ischem
hepat
injuri
acetaminopheninduc
hepat
injuri
peak
ast
ul
case
valu
virtual
never
seen
acut
viral
hepat
toxic
ischem
hepat
injuri
caus
case
acut
hepat
injuri
ast
activ
ul
ischem
acetaminophen
hepat
injuri
ast
alt
activ
typic
peak
earli
often
first
h
admiss
ast
activ
initi
higher
alt
peak
activ
fall
rapidli
ast
may
fall
first
h
declin
rapidli
alt
shorter
halflif
ast
activ
reach
near
normal
valu
averag
day
injuri
pt
refer
limit
case
fall
rapidli
peak
ast
reach
bilirubin
mgdl
case
toxic
ischem
injuri
lactat
dehydrogenas
ec
activ
often
higher
ast
present
toxic
ischem
hepat
injuri
wherea
increas
initi
determin
case
viral
hepat
averag
valu
slightli
upper
refer
limit
rare
cocain
may
caus
hepat
injuri
usual
patient
coexist
hypotens
rare
wilson
diseas
autoimmun
hepat
aih
discuss
detail
chronic
hepat
injuri
present
acut
hepat
injuri
tabl
sever
virus
classic
agent
hav
hbv
hcv
hepat
e
viru
hev
associ
hepat
includ
herpesviru
cytomegaloviru
cmv
enteroviru
coronaviru
reoviru
neonat
adenoviru
parvoviru
pediatr
popul
varicellazost
viru
epsteinbarr
viru
ebv
syphili
leptospirosi
toxoplasmosi
also
may
caus
hepat
injuri
may
less
common
infecti
agent
rare
disord
includ
lymphoma
buddchiari
syndrom
venoocclus
diseas
may
present
pictur
acut
hepat
injuri
gener
hepat
injuri
associ
etiolog
either
unusu
associ
specif
syndrom
chicken
pox
varicellazost
viru
mononucleosi
ebv
cmv
patient
infecti
caus
hepat
injuri
sign
symptom
suggest
particular
agent
caus
specif
diagnosi
infect
agent
pursu
etiolog
remain
unknown
common
caus
exclud
establish
specif
diagnosi
appear
clinic
indic
superinfect
hepat
virus
may
occur
patient
form
hepat
injuri
exampl
patient
chronic
hcv
alcohol
hepat
may
becom
infect
either
hav
hbv
develop
acut
hepat
result
superimpos
infect
chronic
hepat
acut
increas
aminotransferas
mimick
acut
hepat
injuri
occur
clearanc
hbv
e
antigen
hbeag
emerg
quasispeci
hcv
patient
neg
viral
marker
initi
ast
time
upper
refer
limit
toxic
exposur
ischemia
suspect
iib
patient
neg
viral
marker
enzym
concentr
time
upper
refer
limit
test
must
exclud
possibl
wilson
diseas
aih
iib
test
antibodi
hepat
e
recommend
unit
state
unless
viral
serolog
neg
histori
recent
travel
endem
area
iiie
test
infecti
agent
ebv
cmv
syphili
toxoplasmosi
may
use
caus
evid
iib
aminotransferas
activ
tend
increas
peak
near
onset
jaundic
viral
hepat
fall
gradual
point
onward
activ
tend
fall
slowli
viral
hepat
alcohol
hepat
ast
alt
decreas
averag
per
day
respect
remain
increas
day
respect
hepat
secondari
increas
enzym
occur
case
activ
return
baselin
associ
circul
hav
rna
viral
particl
stool
indic
potenti
transmiss
infect
discuss
ast
alt
fall
rapidli
reach
peak
activ
ischem
toxic
hepat
injuri
form
hepat
injuri
decreas
activ
occur
recoveri
massiv
necrosi
make
enzym
activ
poor
indic
recoveri
aminotransferas
shown
consist
pattern
decreas
need
check
patient
clinic
recov
return
aminotransferas
normal
reliabl
sign
recoveri
hepat
b
c
patient
chronic
hcv
infect
normal
alt
initi
visit
seroconvers
develop
increas
alt
subsequ
followup
hepat
b
ast
alt
may
return
normal
despit
persist
infect
bilirubin
peak
later
aminotransferas
often
week
gradual
decreas
peak
bilirubin
mgdl
unusu
viral
hepat
patient
viral
hepat
peak
valu
mgdl
peak
valu
mgdl
higher
bilirubin
common
hbv
infect
total
bilirubin
declin
proport
increas
often
reach
total
bilirubin
adult
viral
hepat
bilirubin
remain
increas
day
peak
concentr
reach
clear
quickli
children
jaundic
remain
longer
week
adult
hbv
case
form
viral
hepat
prolong
increas
conjug
bilirubin
occasion
occur
viral
hepat
particularli
hav
signifi
poor
prognosi
synthet
function
remain
intact
significantli
increas
bilirubin
uncommon
toxic
ischem
hepat
injuri
serum
bilirubin
begun
decreas
reason
measur
unless
jaundic
worsen
clinic
increas
pt
common
find
ischem
toxic
hepat
injuri
often
result
refer
limit
rapidli
return
normal
data
extent
increas
affect
prognosi
ischem
hepat
injuri
increas
pt
refer
limit
viral
alcohol
hepat
marker
sever
diseas
pt
refer
limit
bilirubin
mgdl
develop
encephalopathi
identifi
highrisk
patient
requir
close
monitor
consider
referr
gastroenterologist
hepatologist
iib
patient
acut
hepat
b
repeat
hbsag
measur
perform
within
month
neg
test
antihbv
surfac
antigen
antibodi
antihb
posit
addit
followup
need
iie
patient
acut
hepat
c
alt
measur
period
next
year
assur
continu
normal
result
iib
absenc
liver
biopsi
show
chronic
hepat
one
follow
clinic
definit
use
diagnos
chronic
hepat
persist
increas
alt
month
episod
acut
hepat
orincreas
alt
without
anoth
explan
one
occas
period
month
shorter
time
may
appropri
patient
risk
factor
chronic
viral
hepat
genet
caus
hepat
injuri
autoimmun
liver
injuri
presenc
clinic
sign
symptom
liver
diseas
iib
although
definit
chronic
hepat
injuri
increas
alt
wide
accept
patient
chronic
hepat
c
persist
normal
alt
likelihood
continu
normal
alt
decreas
increas
number
measur
even
three
normal
alt
valu
patient
chronic
hcv
viremia
subsequ
develop
persist
increas
alt
alt
often
fluctuat
normal
abnorm
particularli
chronic
hepat
c
patient
multipl
alt
measur
least
occasion
normal
alt
valu
dr
dufour
unpublish
observ
major
patient
persist
normal
alt
histolog
evid
chronic
hepat
biopsi
gener
milder
inflamm
less
fibrosi
lower
rate
progress
cirrhosi
hcv
patient
increas
alt
center
diseas
control
prevent
guidelin
recommend
treatment
patient
hcv
persist
normal
alt
although
longterm
studi
need
appear
clinic
definit
propos
miss
signific
group
patient
requir
benefit
treatment
alway
possibl
distinguish
acut
chronic
hepat
injuri
patient
chronic
hepat
c
common
form
chronic
hepat
injuri
alt
valu
one
four
time
upper
refer
limit
maximum
alt
less
seven
time
upper
refer
limit
valu
lower
typic
seen
acut
hepat
case
howev
peak
alt
may
time
upper
refer
limit
often
associ
jaundic
pattern
similar
seen
acut
hepat
injuri
dr
dufour
unpublish
observ
case
often
necessari
addit
test
rule
anoth
caus
acut
hepat
injuri
screen
chronic
hepat
recommend
asymptomat
highrisk
individu
iib
iie
alt
costeffect
screen
test
metabol
druginduc
liver
injuri
ast
also
measur
histori
alcohol
abus
iib
iie
specif
viral
serolog
hbsag
antihcv
well
alt
use
individu
high
risk
viral
hepat
ib
confirm
chronic
hcv
infect
antihcvposit
individu
made
hcv
rna
test
neg
alt
increas
hcv
rna
repeat
iib
initi
evalu
includ
detail
drug
histori
along
measur
hbsag
antihcv
antihcv
posit
chronic
infect
confirm
qualit
hcv
rna
measur
iib
iie
persist
increas
alt
neg
viral
marker
workup
includ
antinuclear
antibodi
ana
iron
ironbind
capac
unsatur
ironbind
capac
iiib
patient
age
ceruloplasmin
also
measur
iiib
patient
neg
marker
phenotyp
may
use
iiib
test
neg
inconclus
diagnost
liver
biopsi
perform
iiib
occurr
chronic
liver
diseas
histolog
resembl
alcohol
hepat
patient
without
alcohol
abus
term
nash
common
caus
chronic
hepat
injuri
virus
alcohol
common
caus
cryptogen
cirrhosi
although
nash
occur
commonli
middleag
women
obes
andor
diabet
also
occur
men
patient
without
risk
factor
patient
nash
commonli
abnorm
lipid
profil
although
normal
result
rule
diseas
differ
alcohol
hepat
alt
activ
higher
ast
except
patient
cirrhosi
weight
loss
may
caus
signific
improv
enzym
result
one
studi
reduct
weight
produc
decreas
alt
activ
biopsi
necessari
establish
diagnosi
nash
iib
autosom
recess
trait
hemochromatosi
common
inherit
genet
defect
person
northern
european
ancestri
unit
state
vast
major
case
produc
one
two
point
mutat
hfe
gene
chromosom
major
affect
individu
homozyg
mutat
wherea
minor
compound
heterozygos
mutat
mutat
screen
involv
detect
increas
transferrin
satur
satur
serum
iron
ironbind
capac
low
unsatur
ironbind
capac
transferrin
satur
cutoff
unsatur
ironbind
capac
cutoff
sensit
homozygos
mutat
fast
specimen
use
specif
recent
consensu
confer
recommend
definit
diagnosi
made
genet
analysi
although
sever
recent
public
shown
feasibl
hemochromatosi
screen
use
transferrin
satur
organ
research
current
recommend
screen
unresolv
issu
regard
abil
convinc
young
adult
test
specif
reproduc
screen
test
question
natur
histori
untreat
diseas
screen
advoc
colleg
american
pathologist
estim
save
per
blood
donor
screen
initi
evalu
hemochromatosi
fast
serum
transferrin
satur
unsatur
ironbind
capac
iib
transferrin
satur
unsatur
ironbind
capac
follow
analysi
hfe
gene
mutat
iib
screen
popul
may
benefici
current
recommend
pend
clarif
screen
benefit
iib
iie
autosom
recess
disord
wilson
diseas
occur
individu
europ
north
america
caus
mutat
gene
chromosom
code
atpas
need
copper
transport
wilson
diseas
may
present
liver
diseas
neurolog
problem
psychiatr
symptom
almost
alway
age
patient
present
liver
diseas
neurolog
manifest
common
diagnost
find
low
plasma
ceruloplasmin
low
concentr
also
occur
malnutrit
protein
loss
advanc
liver
diseas
fals
normal
valu
occur
pregnanc
estrogen
administr
acut
inflamm
refer
report
low
ceruloplasmin
homozygot
heterozygot
one
studi
found
normal
ceruloplasmin
patient
chronic
liver
diseas
attribut
wilson
diseas
confirm
genet
studi
patient
wilson
diseas
without
overt
liver
involv
expect
find
wilson
diseas
includ
increas
serum
free
copper
decreas
total
serum
copper
increas
urin
copper
excret
increas
liver
copper
content
test
may
also
provid
mislead
result
patient
wilson
diseas
multipl
test
frequent
need
establish
diagnosi
test
wilson
diseas
ceruloplasmin
indic
patient
age
chronic
hepat
injuri
fatti
liver
neg
workup
viral
hepat
druginduc
liver
injuri
hemochromatosi
iib
screen
wilson
diseas
patient
chronic
hepat
injuri
indic
iib
iie
genet
marker
test
may
use
equivoc
case
test
must
abl
detect
multipl
mutat
wilson
diseas
gene
iiib
aih
respons
chronic
hepat
attribut
virus
alcohol
sever
variant
aih
describ
type
found
primarili
young
middleag
women
common
form
associ
high
titer
ana
andor
antismooth
muscl
antibodi
asma
type
found
primarili
children
common
western
europ
rare
unit
state
associ
antibodi
liverkidney
microsom
antigen
rare
posit
ana
asma
mani
patient
type
also
hcv
infect
type
found
primarili
young
women
associ
system
autoimmun
diseas
mani
case
affect
individu
lack
ana
asma
antiliverkidney
microsom
antibodi
posit
antibodi
solubl
liver
antigen
standard
diagnost
criteria
score
system
defin
intern
panel
classic
featur
common
type
includ
increas
aminotransferas
minim
increas
alp
polyclon
hypergammaglobulinemia
least
time
upper
refer
limit
evid
viral
infect
risk
factor
viral
infect
exposur
drug
alcohol
posit
ana
asma
least
approxim
patient
chronic
hcv
infect
posit
ana
asma
usual
low
titer
falseposit
antihcv
result
report
patient
aih
secondgener
test
use
thirdgener
assay
use
antihcv
typic
disappear
success
treatment
equivoc
case
hcv
rna
recombin
immunoblot
assay
use
establish
diagnosi
aih
suspect
patient
chronic
hepat
injuri
increas
immunoglobulin
absenc
viral
marker
risk
factor
viral
hepat
iiib
diagnosi
type
aih
clinic
support
posit
either
ana
asma
high
titer
iiib
primari
biliari
cirrhosi
pbc
primari
scleros
cholang
psc
autoimmun
diseas
caus
destruct
bile
duct
although
pbc
psc
characterist
caus
increas
alp
ec
patient
diseas
may
increas
ast
alt
consid
chronic
hepat
pbc
associ
destruct
intrahepat
bile
duct
often
associ
autoimmun
disord
particularli
sjogren
syndrom
case
autoimmun
marker
antimitochondri
antibodi
ama
found
almost
patient
pbc
although
diseas
may
associ
posit
ama
pbc
antibodi
direct
pyruv
dehydrogenas
complex
socal
type
ama
particularli
dihydrolipoamid
acetyltransferas
protein
approxim
patient
featur
pbc
aih
pbc
often
detect
asymptomat
individu
find
increas
alp
ast
alt
increas
approxim
onehalf
case
although
valu
two
time
refer
limit
psc
associ
damag
intra
extrahepat
bile
duct
case
associ
inflammatori
bowel
diseas
crohn
diseas
ulcer
coliti
perinuclear
antineutrophil
cytoplasm
antibodi
found
approxim
twothird
case
psc
antibodi
commonli
direct
bactericidalpermeabilityincreas
protein
cathepsin
g
andor
lactoferrin
appear
prognost
signific
differ
antibodi
specif
although
patient
cirrhosi
commonli
antibodi
multipl
antigen
antigen
lactoferrin
asma
ana
also
present
case
pbc
psc
suspect
patient
chronic
cholestasi
iiib
diagnosi
clinic
support
posit
ama
pbc
antineutrophil
cytoplasm
antibodi
psc
high
titer
iiib
import
proteas
inhibitor
congenit
defici
occur
person
european
ancestri
gene
locat
chromosom
defici
usual
attribut
singl
amino
acid
substitut
alter
carbohydr
bind
impair
releas
hepatocyt
import
defici
involv
homozygos
z
variant
term
pi
proteas
inhibitor
zz
defici
associ
emphysema
neonat
hepat
chronic
hepat
injuri
cirrhosi
hcc
also
report
almost
pi
zz
neonat
evid
liver
injuri
birth
usual
resolv
age
year
adult
pi
zposit
individu
either
homozygot
heterozygot
develop
cirrhosi
develop
hcc
also
excess
pi
z
heterozygot
among
patient
refer
liver
transplant
particularli
among
patient
cryptogen
cirrhosi
patient
pi
z
posit
evid
howev
defici
heterozygos
pi
z
phenotyp
may
directli
caus
liver
diseas
increas
suscept
liver
damag
agent
especi
virus
two
control
studi
found
frequenc
pi
z
either
homozyg
heterozyg
patient
liver
diseas
control
studi
patient
pi
z
chronic
liver
diseas
also
posit
hcv
antibodi
hbv
marker
liver
diseas
risk
factor
acut
phase
reactant
quantit
concentr
may
fals
normal
infect
inflamm
fals
low
concentr
may
occur
malnutrit
proteinlos
state
end
stage
liver
diseas
one
studi
quantit
concentr
normal
heterozyg
pi
z
patient
liver
diseas
test
defici
use
phenotyp
analysi
rather
quantit
plasma
concentr
test
defici
may
benefit
patient
chronic
hepat
injuri
appar
caus
although
role
defici
liver
diseas
adult
clearli
defin
iib
test
especi
import
neonat
evid
hepat
injuri
iib
test
variant
perform
determin
phenotyp
iib
screen
patient
chronic
hepat
injuri
defici
recommend
iiib
iiie
test
hgv
ttv
research
set
recommend
iiie
viral
hepat
viral
marker
reliabl
marker
resolut
hepat
iib
hcv
rna
quantif
genotyp
import
determin
durat
combin
therapi
reduc
expens
test
feasibl
specimen
obtain
treatment
store
pend
result
treatment
possibl
test
perform
treatment
begun
iib
iie
patient
hcv
treat
interferon
ribavirin
qualit
hcv
rna
measur
week
treatment
determin
potenti
respond
genotyp
quantit
hcv
rna
perform
specimen
frozen
analysi
treatment
neg
hcv
rna
favor
risk
factor
test
perform
ib
ie
patient
hcv
treat
interferon
monotherapi
qualit
hcv
rna
alt
measur
week
treatment
determin
nonrespond
iib
follow
treatment
neg
hcv
rna
week
sensit
hcv
rna
measur
current
qualit
assay
perform
month
end
treatment
document
sustain
virolog
remiss
iib
untreat
patient
hbv
hbeag
monitor
period
hbeag
neg
antihb
posit
hbsag
monitor
period
determin
viral
clearanc
antivir
therapi
hbv
dna
also
use
document
viral
clearanc
iib
treat
patient
complet
blood
count
platelet
measur
everi
week
first
week
monthli
thereaft
thyroidstimul
hormon
measur
everi
month
sooner
symptom
thyroid
dysfunct
develop
measur
alt
perform
least
monthli
iiib
alt
best
marker
inflammatori
activ
avail
limit
util
predict
degre
inflamm
use
estim
sever
fibrosi
iib
biopsi
definit
marker
progress
chronic
hepat
cirrhosi
iib
laboratori
marker
fibrosi
use
except
research
studi
iiib
iiie
marker
hepat
function
may
indic
progress
cirrhosi
ast
alt
ratio
albumin
pt
platelet
count
measur
everi
month
patient
chronic
hepat
iiib
screen
hcc
question
benefit
western
popul
iib
iie
screen
confin
highrisk
patient
sever
chronic
hepat
cirrhosi
attribut
alcohol
hbv
hcv
hemochromatosi
candid
treatment
hcc
detect
iiib
iiie
screen
use
measur
afp
ultrasound
interv
frequent
everi
month
recommend
iib
current
data
support
use
test
iiib
